

RECEIVED

NOV 22 2002

CH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Commissioner for Patents, Washington, D.C. 20231, on the date noted below:

Date: November 15, 2002

*Sean Mellino*  
Sean Mellino



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert Peter Klein, et al.  
Serial No. : 09/720,287 (Conf. No.: 1252)  
Filed : May 10, 2001  
Title : Transdermal Therapeutic System Containing Hormones and Crystallization Inhibitors  
Examiner : Isis Ghali  
Art Unit : 1615  
Attorney Docket : RO0208US (#90568)

Box Response – Fee  
Commissioner for Patents  
Washington D.C., 20231

CLEAN CLAIMS

*Sub  
G32*

1. (Twice amended) A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising:  
a backing layer; and  
a reservoir supersaturated with active ingredients and containing oestradiol and norethisterone acetate, said reservoir is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors; and is a detachable protective layer, wherein the crystallization inhibitor is an amino group -containing polymer selected from the group consisting of polyaminoamides,

82  
Cost

polyaminoimidazolines, polyetherurethaneamines, polyamines, polyglucosamines and a copolymer based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate being present in a molar ratio of 1:2:1 (butyl methacrylate : 2-dimethylaminoethyl methacrylate : methyl methacrylate).

- B3
3. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir comprises at least one crystallization inhibitor in proportion of from 0.05 to 30% by weight.
  4. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, and in an overall concentration of up to 25% by weight.
  5. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir includes a constituent from the group consisting of aging inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizers being used in a concentration of 0 to 5% by weight and the aging inhibitor in a concentration of 0.1 to 2% by weight.
  6. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the pressure-sensitive adhesive is selected from the group consisting of a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive and a UV-crosslinkable adhesive.
  7. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir consists of at least two layers.
  8. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir has a layer thickness of 0.02 mm to 0.500 mm.
  9. (Twice amended) A transdermal therapeutic system according to claim 1, wherein the reservoir is provided with an additional pressure-sensitive adhesive layer.

11. (Amended) A transdermal therapeutic system according to claim 4, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:3 to 1:7.

BE/ 12. (Amended) A transdermal therapeutic system according to claim 8, wherein the reservoir has a layer thickness of 0.030 to 0.200 mm.

13. (Amended) A transdermal therapeutic system according to claim 9, wherein the reservoir is provided with a pressure-sensitive adhesive margin.

14. (Amended) A transdermal therapeutic system according to claim 1, wherein the reservoir is provided with a pressure-sensitive adhesive margin.

15. (Amended) A method for providing a transdermal therapeutic system for therapeutic applications in human medicine, said method comprising:

applying said transdermal therapeutic system to the skin of a patient by applying a polyacrylate pressure-sensitive adhesive to said transdermal therapeutic system; and

controlling the release of oestradiol in combination with norethisterone acetate to the human skin by providing a reservoir in said transdermal therapeutic system, said reservoir being supersaturated with active ingredients and being attached to a backing layer, wherein said reservoir comprises at least one amino group-containing polymer and at least one adhesive selected from the group consisting of a polyacrylate pressure-sensitive adhesive layer and a pressure-sensitive adhesive margin.